Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Both organisations enter into a long- term collaboration to expand patient access in India
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
It is the first autotaxin inhibitor to be investigated in cancer patients
The investment will catalyse various components of the IndiaAI Mission
The facility will manufacture Specialty and Fine Chemicals tailored to various applications across industries such as Polymer and Water Treatment facilities
Acquisition of exclusive commercialization rights for European markets
Pfizer INDovation program partners with NIPER Ahmedabad to incubate healthcare startups
Subscribe To Our Newsletter & Stay Updated
